Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -0.0%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $8M | $9M | $16M | $20M | — | — | — |
| Enterprise Value | $3M | $4M | $11M | $17M | — | — | — |
| P/E Ratio → | -1.04 | — | — | — | — | — | — |
| P/S Ratio | 72.68 | 78.23 | — | 303.42 | — | — | — |
| P/B Ratio | 0.00 | 0.00 | 3.32 | 7.61 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 31.64 | — | 263.04 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 17.3% | 17.3% | — | 92.0% | 92.0% | — | — |
| Operating Margin | -5652.4% | -5652.4% | — | -8257.7% | -24558.0% | — | — |
| Net Profit Margin | -5569.6% | -5569.6% | — | -8239.8% | -28024.9% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -0.0% | -0.0% | -185.1% | -206.6% | — | — | — |
| ROA | -0.0% | -0.0% | -167.9% | -374.9% | -6201.4% | -7794.1% | -6807.9% |
| ROIC | -0.0% | -0.0% | — | — | — | — | — |
| ROCE | -0.0% | -0.0% | -191.5% | -207.1% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.00 | -1.10 | -1.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -1171.55 | -1171.55 | -384.16 | -66.72 | -7.07 | -13.50 | -28.04 |
Net cash position: cash ($5M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.85 | 3.85 | 9.43 | 15.03 | 0.02 | 0.01 | 0.01 |
| Quick Ratio | 3.85 | 3.85 | 9.43 | 15.03 | 0.02 | 0.01 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 9.24 | 14.24 | 0.02 | 0.01 | 0.01 |
| Asset Turnover | — | 0.00 | — | 0.02 | 0.12 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $10M | $8M | $6M | $6M | $6M | $6M |
Rapid Cash Runway Depletion
According to current market data, BFRG trades at a price-to-sales multiple of 72.68, which appears significantly detached from its negligible revenue base and suggests that investors are pricing the stock as a speculative option on future clinical milestones rather than a functional, revenue-generating technology business.
The extreme P/S ratio indicates that the market is assigning value to the company's intellectual property and licensing rights rather than its current operational output. This valuation level implies an expectation of non-linear growth that remains unsupported by the company's historical performance or current commercial trajectory.
As reported in financial statements, the company's operating margin of -5652.38% highlights a profound structural disconnect between its high fixed-cost base and its current ability to generate meaningful revenue, suggesting that the firm is currently in a pre-commercial phase that is heavily reliant on external capital.
The gross margin of 17.29% is notably low for a firm positioned as an AI-driven software provider, implying that the company incurs significant direct costs to deliver its services. This suggests that the business model may be more service-intensive than scalable, which warrants further investigation into whether future margins can expand as the platform matures.
Based on the most recent quarterly filings, the company's current ratio has compressed from 15.03 in 2023Q4 to 8.15 in 2026Q1, reflecting a steady erosion of the firm's liquid assets as it continues to fund its substantial operating losses without a corresponding inflow of new revenue.
While the current ratio remains numerically high, the rapid decline suggests that the company's cash runway is being consumed at an unsustainable pace. Investors should monitor the company's ability to maintain this liquidity buffer, as any further contraction could necessitate dilutive financing to support ongoing research and development activities.
The use of price-to-sales ratios to evaluate BFRG is fundamentally flawed, as the company's current revenue of $116,670 is project-based and non-recurring, failing to capture the underlying value of the firm's licensed therapeutic assets or the potential of its proprietary bfLEAP platform.
Analysts should instead focus on clinical milestone progression and the velocity of new partnership signings, as these metrics provide a more accurate reflection of the company's potential value creation. Relying on traditional valuation multiples in this context obscures the high-variance, binary nature of the firm's business model.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BFRG stock.
Bullfrog AI Holdings, Inc. Common Stock's current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
Bullfrog AI Holdings, Inc. Common Stock's return on equity (ROE) is -0.0%. The historical average is -130.6%.
Based on historical data, Bullfrog AI Holdings, Inc. Common Stock is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bullfrog AI Holdings, Inc. Common Stock has 17.3% gross margin and -5652.4% operating margin.